Preview

Meditsinskiy sovet = Medical Council

Advanced search

TREATMENT OF DIABETIC DISTAL POLYNEUROPATHY WITH ACTOVEGIN® IN TYPE 2 DIABETIC PATIENTS.

https://doi.org/10.21518/2079-701X-2017-11-162-164

Abstract

The possibilities of treatment of diabetic polyneuropathy with Actovegin® are discussed in this publication.  In the multicenter, randomized, double-blind trial 567  patients  with type 2  diabetes  received 20  intravenous infusions of 20% solution  of Actovegin® or placebo followed by 1800  mg of Actovegin® in tablets or placebo for 140 days. The effectiveness was assessed by changes of Total Symptom Score and vibration perception as primary outcomes, neuropathy impaired score of the lower limbs (NIS-LL) and quality of life as secondary end points. Treatment with Actovegin resulted in significant improvement in TSS (p = 0,0003), sensory component of NIS-LL (p = 0,021), improvement of vibration perception (р = 0,08) and mental domain of quality of life. Thus, treatment of diabetic distal polyneuropathy with Actovegin® in type 2 diabetic patients improves different functions of peripheral nervs.

About the Authors

E. U. Komelyagina
Endocrinology Dispensery of the Department of health of Moscow city
Russian Federation


M. B. Antsiferov
Endocrinology Dispensery of the Department of health of Moscow city
Russian Federation


References

1. International guidelines on the out-patient management of diabetic peripheral neuropathy, 1996.

2. Shaw JE, Zimmet PZ, Gries FA, Ziegler D. Epidemiology of Diabetic Neuropathy. In: Gries FA, Cameron NE, Low PA, Ziegler D (Eds.). Textbook of diabetic neuropathy. Thieme, Stuttgart, New York, 2003: 64-82.

3. Ziegler D, Rathmann W, et al. for the KORA Study Group. Prevalence of Polyneuropathy in Prediabetes and Diabetes is Associated with Abdominal Obesity and Macroangiopathy. The MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care, 31: 2008, 464-9.

4. Daosi C, Bendow SJ, Woodward A, MacFarlane IA. The natural history of chronic painful peripheral neuropathy in a community diabetes population. Diabet Med, 2006, 23: 1021-4.

5. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care, 2006, 29: 1518-22.

6. Комелягина Е.Ю., Анциферов М.Б., Уварова О.М. Русскоязычная версия опросника для оценки качества жизни у больных с периферической полинейропатией: валидация и перспективы применения. Сахарный диабет, 2014, 17(2): 56-65.

7. Циглер Дан. Диабетическая периферическая нейропатия: клинические проявления, диагностика и лечение. М., 2009.

8. Elmlinger MW, Kriebel M and Ziegler D. Neuroprotective and anti-oxidative effects of the hemodialysate actovegin on primary ratneurons in vitro. Neuromolecular Med, 2011, 13: 266-274.

9. Dieckmann A, Kriebel M, Andriambeloson E et al. Treatment with Actovegin (R) improves sensory nerve function and pathology in streptozotocin-diabetic rats via mechanisms involving inhibition of PARP activation. Exp. Clin. Endocrinol. Diabetes, 2012, 120: 132-138.

10. Jansen W, Beck E. Treatment of the diabetic polyneuropathy: a controlled double blind study. Med Welt, 1987, 38: 838-841.

11. Abbott CA, Vileikyte L, Williamson S et al. Multicenter study ofthe incidence ofand predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care, 1998, 21(7): 1071-1075.

12. Ряженов В.В., Горохова С.Г. Различные стратегии ведения пациентов с диабетической полинейропатией: моделирование клинических исходов и фармакоэкономический анализ. Эффективная фармакотерапия, 2017, 8: 14-18.

13. Ziegler D, Movsesyan L, Mankovsky B, Gurieva I, Abylaiuly Z, Strokov I. Treatment of Symptomatic Polyneuropathy With Actovegin in Type 2 Diabetic Patients. Diabetic Care, 2009, August 20, 32(8): 1479-1484.

14. Abbot CA, Vileikyte L, Williamson S et al. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care, 1998, 21: 1071-1075.

15. Фокина А.С., Строков И.А., Зилов А.В. Актовегин в лечении субклинической дистальной симметричной сенсорно-моторной полиневропатии. Медицинский совет, 2016, 11: 2-7.


Review

For citations:


Komelyagina EU, Antsiferov MB. TREATMENT OF DIABETIC DISTAL POLYNEUROPATHY WITH ACTOVEGIN® IN TYPE 2 DIABETIC PATIENTS. Meditsinskiy sovet = Medical Council. 2017;(11):162-164. (In Russ.) https://doi.org/10.21518/2079-701X-2017-11-162-164

Views: 916


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)